Testosterone gel - Upsher-Smith Laboratories

Drug Profile

Testosterone gel - Upsher-Smith Laboratories

Alternative Names: Testosterone Gel CIII; USL240; Vogelxo

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Upsher-Smith
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypogonadism

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Feb 2015 The US FDA grants AB rating to testosterone gel (Vogelxo™)
  • 04 Jun 2014 Registered for Hypogonadism in USA (Topical) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top